EPO and retinopathy of prematurity: The effect of EPO on ROP depends on the timing of administration; it may reduce vaso-obliteration if administered during phase I ROP, whereas it appeared to increase the risk of ROP at any grade in a previous retrospective study (Kandasamy et al., 2014).